Gabapen 300 Tablet
Gabapentin
300mg
Incepta Pharmaceuticals Ltd.
| Pack size | 30's pack |
|---|---|
| Unite Price | 16 BDT |
Indications
Gabapen 300 Tablet is used for:
Epilepsy, Neuropathic pain, Partial Seizures, Hot flashes, Fibromyalgia, Postherpetic Neuralgia, Pain from diabetic neuropathy.
Adult Dose
Partial Seizures
Adjunctive therapy for partial seizures with or without secondary generalization
Initial: 300 mg PO q8hr
May increase up to 600 mg PO q8hr; up to 2400 mg/day administered and tolerated in clinical studies; up to 3600 mg administered for short duration and tolerated
Postherpetic Neuralgia
Day 1: 300 mg PO qDay
Day 2: 300 mg PO q12hr
Day 3: 300 mg PO q8hr
Maintenance: Subsequently titrate as needed up to 600 mg PO q8hr; doses >1800 mg/day have demonstrated no additional benefit
Restless legs syndrome
100-300 mg PO 2 hr before bedtime on first day; may titrate every 2 weeks until symptom relieve achieved (range 300-1800 mg/day)
Diabetic Neuropathy
900 mg/day PO initially; may increase gradually q3Days to 1800-3600 mg/day
Hot flashes-cancer related
200-1600 mg PO qDay to q6hr for 4-8 weeks
Child Dose
Partial Seizures
Adjunctive therapy for partial seizures with or without secondary generalization in patients older than 12 years of age with epilepsy; also indicated as adjunctive therapy for partial seizures in pediatric patients aged 3-12 years
<3 years: Safety and efficacy not established
3-12 years (initial dose): 10-15 mg/kg/day PO divided q8hr initially; titrate up in approximately 3 days to effective maintenance dose
3-4 years (maintenance dose): 40 mg/kg/day PO divided q8hr
5-12 years (maintenance dose): 25-35 mg/kg/day PO divided q8hr
>12 years (initial dose): 300 mg PO q8hr; may increase up to 600 mg PO q8hr
Renal Dose
Renal impairment
CrCl >60 mL/min: 300-1200 mg PO TID
CrCl 30-60 mL/min: 200-700 mg q12hr
CrCl 15-29 mL/min: 200-700 mg qDay
CrCl <15 mL/min: 100-300 mg qDay
Hemodialysis (CrCl <15 mL/min): Administer supplemental dose (range 125-350 mg) posthemodialysis, after each 4 hr dialysis interval; further dose reduction should be in proportion to CrCl (eg, CrCl of 7.5 mL/min should receive one-half daily posthemodialysis dose)
Administration
May be taken with or without food.
Contra Indications
Hypersensitivity. Lactation.
Precautions
Discontinuation or transfer from other antiepileptics, history of psychotic illness; renal impairment; pregnancy. Gradual withdrawal over at least 7 days to prevent an increase in seizure frequency.
Lactation: Enters breast milk; use with caution
Pregnancy-Lactation
Pregnancy
There are no adequate data on developmental risks associated with use in pregnant women; in nonclinical studies in mice, rats, and rabbits, the drug was developmentally toxic (increased fetal skeletal and visceral abnormalities, and increased embryofetal mortality) when administered to pregnant animals at doses similar to or lower than those used clinically
Lactation
Gabapentin is secreted in human milk following oral administration; effects on breastfed infant and on milk production are unknown; developmental and health benefits of breastfeeding should be considered along with mother's clinical need for therapy and any potential adverse effects on breastfed infant from treatment or from underlying maternal condition
Interactions
May increase plasma level w/ morphine. Reduced absorption w/ antacids.
Side Effects
Side effects of Gabapentin :
>10%
Ataxia (1-13%), Dizziness (16-20%), Drowsiness (5-21%), Fatigue (11-15%), Somnolence (16-20%)
1-10%
Diplopia (6-10%), Nystagmus (6-10%), Tremor (6-10%), Amblyopia (1-5%), Back pain (1-5%), Constipation (1-5%), Depression (1-5%), Dry mouth (1-5%), Dysarthria (1-5%), Dyspepsia (1-5%), Hostility (5-8% children), Hyperkinesia (3-5%), Increased appetite (1-5%), Leukopenia (1-5%), Myalgia (1-5%), Nervousness (1-5%), Peripheral edema (1-5%), Pharyngitis (1-5%), Pruritus (1-5%), Rhinitis (1-5%), Vasodilation (1-5%), Weight gain (1-5%), Abnormal vision (>1%), Anorexia (>1%), Arthralgia (>1%), Asthenia (>1%), HTN (>1%), Malaise (>1%), Paresthesia (>1%), Purpura (>1%), Vertigo (>1%)
Mode of Action
Gabapentin is structurally related to the neurotransmitter GABA but is neither a GABA agonist nor antagonist. High affinity gabapentin binding sites are located throughout the brain. These sites correspond to the presence of voltage-gated Ca channels particularly controlling the ?-2/?-1 subunit. This channel appears to be located presynaptically and may modulate the release of excitatory neurotransmitters which participate in epileptogenesis and nociception.
Note
Gabapen 300 300mg Tablet generic name is Gabapentin. Gabapen 300 300mg Tablet is manufactured by Incepta Pharmaceuticals Ltd.Gabapen 300 is availble in all over Bangladesh.
Mes BD drug index information on Gabapen 300 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.